2019 CYIR Finalized

35 (28.8%, p=0.5). Both trials demonstrated improved shock resolution (secondary outcome), with low rates of serious adverse events other than hyperglycemia with bolus glu- cocorticoids. Comments 1. These two trials cumulatively examined the role of low-dose hydrocortisone in over 5,000 patients with septic shock and found a difference in the primary outcome (90-day mortality) between the trials, but similar benefits in the secondary out- come of resolution of shock in both studies. 2. Patients in the ADRENAL trial received a hydrocortisone infu- sion, rather than bolus doses of hydrocortisone, such that the time to a therapeutic drug level might take longer. 3. While the ADRENAL trial did not use adjunctive fludrocortisone, a prior study did not suggest different effects than with hydro- cortisone alone. 4. Patients in the APROCCHSS were sicker than in the ADRENAL trial, as judged by a number of factors, including higher mortal- ity. 5. While there is no clear answer as to the definitive role of low- dose steroids in septic shock, these new papers do not refute current guidelines suggesting low-dose hydrocortisone for septic patients with refractory shock without a contraindication to corticosteroids, and suggest that the benefit of steroids may outweigh the risk in sicker patients, in particular. FLUID RESUSCITATION IN CRITICAL ILLNESS Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, Stollings JL, Kumar AB, Hughes CG, Hernandez A, Guillamondegui OD, May AK, Weavind L, Casey JD, Siew ED, Shaw AD, Bernard GR, Rice TW for the SMART Investigators and the Pragmatic Critical Care Research Group. Balanced crystalloids versus saline in critically ill adults. N Engl J Med 2018; 378:829- 839. Summary The optimal solution for fluid resuscitation in critically ill patients has long been debated. Some studies have raised concern that intravenous saline may be associated with adverse events, including acute kidney injury and death. Additional studies suggested that use of balanced crystal- loid solutions that more closely resemble the electrolyte composition of plasma might be associated with lower rates of renal injury and death, though results from the literature have been conflicting. This recent single-center study [Isotonic Solutions and Major Adverse Renal Events Trial (SMART)] used a pragmatic, cluster-randomized, multiple-crossover trial in five ICUs (including medical and nonmedical ICUs) in a single academic center to compare 0.9% saline vs. balanced crystalloids (lactated Ringer’s solution or Plasma-Lyte A based on the treating clinician’s preference) in 15,802 adult subjects. The investigators demonstrated a 1.1% improvement with balanced crystal- loids in the primary outcome of a major adverse kidney event within 30 days (a composite outcome of death from any cause, new renal replacement therapy, or persistent renal dysfunction defined as an elevation of creatinine to greater than or equal to 200% of baseline). Comments 1. In this study, use of balanced crystalloids produced a lower rate of the composite outcome (death from any cause, new renal- replacement therapy, or persistent renal dysfunction) compared with saline in ICU patients. 2. The effect size observed in this trial was modest, but if these findings apply to the large numbers of patients admitted to ICUs throughout the world yearly, the potential benefits could have broader impact. 3. Given relative hypotonicity of balanced crystalloids, clinicians treating patients with brain injury in this trial were given the option of administering 0.9% sodium chloride, so the findings of this study cannot be applied to the subgroup of ICU patients with traumatic brain injury. 4. The composite outcome was driven in large part by a reduc- tion in persistent acute kidney injury at day 30 and supports the potential notion that the chloride load of 0.9% saline might have injurious renal effects. 5. These interesting results from a single center open-label study using a primary composite outcome have prompted some clini- cians and studies to favor use of balanced crystalloids and will need to be interpreted by each clinician as it might apply to their individual patients. TIMING OF RENAL REPLACEMENT THERAPY IN CRITICAL ILLNESS Barbar SD, Clere-Jehl R, Bourredjem A, Hernu R, Montini F, Bruyère R, Lebert C, Bohé J, Badie J, Eraldi JP, Rigaud JP, Levy B, Siami S, Louis G, Bouadma L, Constantin JM, Mercier E, Klouche K, du Cheyron D, Piton G, Annane D, Jaber S, van der Linden T, Blasco G, Mira JP, Schwebel C, Chimot L, Guiot P, Nay MA, Meziani F, Helms J, Roger C, Louart B, Trusson R, Dargent A, Binquet C, Quenot JP; IDEAL-ICU Trial Investigators and the CRICS TRIGGERSEP Network. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N Engl J Med 2018; 379:1431-1442. Summary Acute kidney injury (AKI) frequently complicates septic shock and has high mortality. Without definitive indications for renal replacement therapy (RRT) (e.g., hyperkalemia, metabolic acidosis, volume overload), it remains unclear what the appropriate timing of initiation of RRT should be in septic shock. Two recent trials of early vs. delayed initia- tion of RRT produced conflicting results. This multicenter, open-label, controlled trial randomized 488 patients in 29 French ICUs with early septic shock (within 48h of vaso- pressors) and AKI (failure stage of the risk, injury, failure, loss, and end-stage kidney disease [RIFLE] classification defined by: creatinine 3X baseline or at least 4 mg/dl with rapid increase of at least 0.5 mg/dl; or urine output < 0.3 GENERAL CRITICAL CARE

RkJQdWJsaXNoZXIy MTM1ODMw